Trends in antihypertensive drug use in the United States: Do the JNC V recommendations affect prescribing?

JAMA

Volumn 278, Issue 21, 1997, Pages 1745-1748

  Siegel, David ^a,b   Lopez, Julio ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; LISINOPRIL; METOPROLOL; NIFEDIPINE; TERAZOSIN; VERAPAMIL;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CALCIUM ANTAGONISM; DIURESIS; DRUG COST; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0030711521     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.21.1745     Document Type: Article

References (29)

1. Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993; 153:154-183.
2. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988;148:1023-1038.
3. Weber MA, Laragh JH. Hypertension: steps forward and steps backward. Arch Intern Med. 1993; 153:149-152.
4. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507-1513.
5. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of mild hypertension study: final results. JAMA. 1993;270:713-724.
6. Kaplan NM, Gifford RW. Choice of initial therapy for hypertension. JAMA. 1996;275:1577-1580.
7. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
8. Lenfant C. High blood pressure: some answers, new questions, continuing challenges. JAMA. 1996; 275:1604-1606.
9. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drugtherapies. JAMA. 1995;274:620-625.
10. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested. JAMA. 1995; 274:654-655.
11. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
12. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management, of hypertension in the United States. Arch Intent Med. 1995;155:829-837.
13. Psaty BM, Koepsell TD, Yanez D, et al. Temporal patterns of antihypertensive medication use among adults, 1989 through 1992. JAMA. 1995;273: 1436-1438.
14. Top 200 survey. Am Drug. 1993;207:49-53.
15. The top 200 drugs. Am Drug. 1996;212:18-26.
16. Ramspacher S. 1995 Hospital pharmacy review: leading dollar volume pharmaceuticals. Hosp Pharmacy. 1996;31:624-42.
17. 1995 Drug Topics Redbook. Montvale, NJ: Medical Economics Publishing; 1995.
18. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. N Engl J Med. 1993;328:914-921.
19. US Dept of Health and Human Services. Heart Failure: Management of Patients With Left Ventricular Dysfunction. Washington, DC: US Dept of Health and Human Services; June 1994. Agency for Health Care Policy and Research Publication 94-0613.
20. Collins JG. Prevalence of selected chronic conditions: United States, 1986-88. Vital Health Stat 10. 1993;182:1-87.
21. Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA. 1982;247:1707-1714.
22. Conti CR. Re-examining the clinical safety and roles of calcium antagonists in cardiovascular medicine. Am J Cardiol. 1996;78(suppl 9A):13-18.
23. Soumerai SB. Factors influencing prescribing. Aust J Hosp Pharm. 1988;18(suppl):9-16.
24. Soumerai SB, McLaughlin TJ, Avorn J. Improving drug prescribing in primary care: a critical analysis of the experimental literature. Milbank Q. 1989; 67:268-317.
25. Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts' assessments. Ann Intern Med. 1992;116: 912-919.
26. Simonsen LLP. What are pharmacists dispensing most often? Pharm Times. 1993;59:29-44.
27. Top 200 drugs of 1995. Pharm Times. 1996;62: 27-34.
28. Siegel D, Hulley SB, Black DM, et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA. 1992;267:1083-1089.
29. Davis BR, Cutler JA, Gordon DJ, et al, for ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-362.